June 17, 2013
Today, Wall Street Reports announced new research reports highlighting Pfizer Inc. (NYSE: PFE), Merck & Co. Inc. (NYSE: MRK), Bristol-Myers Squibb Company (NYSE: BMY), Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), and Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Pfizer Inc. Research Report
June 12, 2013
, Pfizer Inc. (Pfizer) announced that it has reached a
settlement with Teva Pharmaceuticals and Sun Pharmaceuticals for patent-infringement damages related to the launches of the generic Protonix in the US.
Amy W. Schulman
, Executive Vice President and General Counsel of Pfizer, said, "We are pleased with today's settlement, which recognizes the validity and value of the innovation that led to Protonix." Schulman added, "Protecting intellectual property is vital as we develop new medicines that save and enhance patients' lives." Pfizer will receive 64% of the compensation, and the remaining will be given to Nycomed, which is now part of Takeda. The Full Research Report on Pfizer Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [
Merck & Co. Inc. Research Report
June 12, 2013
, Merck & Co. Inc. (Merck) commented on the NIDDK-NCI Workshop and the American Diabetes Association's (ADA) call for an independent review of data about the safety of incretin-based diabetes medicines, including GLP-1 analogs and DPP-4 inhibitors, such as Januvia (sitagliptin).
, M.D., Chief Medical Officer of Merck, stated, "Nothing is more important to Merck than the safety of our medicines and the people who take them. We welcome opportunities to discuss the data that support the safety profile of sitagliptin in the treatment of adults with type 2 diabetes. Type 2 diabetes is a disease with serious consequences if left untreated." Rosenblatt continued, "We are committed to participating in an independent review of our data, and will join the ADA in planning for such an initiative." The Full Research Report on Merck & Co. Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [